Skip to main content

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.19
+3.50 (1.45%)
AAPL  305.45
+11.07 (3.76%)
AMD  520.09
-20.79 (-3.84%)
BAC  58.58
+0.22 (0.37%)
GOOG  354.66
-3.23 (-0.90%)
META  588.71
-24.20 (-3.95%)
MSFT  388.48
+4.20 (1.09%)
NVDA  195.03
-2.55 (-1.29%)
ORCL  141.60
-0.90 (-0.63%)
TSLA  396.81
-28.49 (-6.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.